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Nowadays, the impact of cardiovascular imaging on
the overall healthcare system is substantial. Every
year ﬁve billion imaging tests are performed world-
wide, and about half of these are cardiovascular
examinations [1–3]. It is estimated that nearly 8
million SPECT studies are now performed annually
in the US compared to 4 million studies in 1998.
Considering the additional 2.8 million stress echo-
cardiograms, the total number of stress imaging
studies in the US was nearly 11 million in 2006. More
importantly, one might measure patient selection,
which is a key variable impacting directly on clinical
management, downstream testing procedures, and
—in particular- costs. Otero et al. [1] have shown that
each test represents a cost and a risk, and that very
small individual costs and risks become signiﬁcant
when multiplied by the large number of tests per-
formed worldwide annually. This important concept
has far-reaching implications. The cost of a medical
imaging test has three different components: imme-
diate cost; long-term cost (for instance, due to a new
cancer developing decades after testing, as a
consequence of the imaging test); and a societal cost
due to the possible environmental impact of the
imaging procedure. The American College of Cardi-
ology (ACC) and the subspecialty imaging societies
have provided this quality issue by focusing on the
development of appropriateness criteria for cardio-
vascular imaging which are designed to deﬁne the
appropriate test for the appropriate indication in the
appropriate patient [4]. According to recent esti-
mates, at least one-third of all examinations are
partially or totally inappropriate, i.e. risks and costs
outweigh beneﬁts. In a context of scarce resources,
and consequently the need to optimize their alloca-
tion, economic evaluation could play an important
role in establishing a cost-effective health care pro-
gram and supporting the decisions of policymakers?
The ﬁrst appropriateness criteria were developed for
SPECT myocardial perfusion imaging followed
shortly thereafter with appropriateness criteria for
echocardiography, cardiac computed tomography
(CT), and cardiac magnetic resonance imaging
(CMR) [5–16]. Both CMR and CT still have a lower
proﬁle in the economic market, but they are growing
steadily [17–41]. CMR is currently not or not
sufﬁciently reimbursed presumably because of lim-
ited evidence-based studies. It is not fully known
whether CMR can be effectively used to facilitate
medical decision-making and reduce costs by serving
as a gatekeeper to invasive coronary angiography.
In the current issue of the International Journal of
Cardiovascular Imaging, Pilz et al. [42] investigated
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coronary artery disease (CAD) reduced costs by
avoiding referrals to invasive procedures. Propensity
score methods were used to match 218 patients from
a CMR registry to a previously studied cohort in
whom CMR was demonstrated to reliably identify
patients who were at low-risk for major cardiac
events. The proportion of patients was assessed for
whom cardiac catheterization was deferred based on
CMR ﬁndings. CMR reduced the utilization of
cardiac catheterization by 62.4%. Based on estimated
catheterization costs of € 619, the utilization of CMR
as a gatekeeper reduced per-patient costs by a mean
of € 90. CMR signiﬁcantly reduced the utilization of
cardiac catheterization in patients suspected of hav-
ing CAD. Per-patient savings ranged from € 323 in
patients at lowest risk of CAD to € 58 in patients at
high-risk. Because a negative CMR study has a high
negative predictive value, its use as a gatekeeper to
cardiac catheterization is a worthwhile option in
patients with suspected CAD who are considered for
cardiac catheterization.
These ﬁndings are in line with previous noninva-
sive imaging studies which clearly showed a gate-
keeper role for SPECT imaging in referral to invasive
coronary arteriography [43, 44]. In the Economics of
Noninvasive Diagnosis (END) study, Shaw et al. [43]
compared two patient management strategies con-
sisting of (1) direct cardiac catheterization (aggres-
sive strategy), or (2) initial SPECT followed
by selective catheterization of high risk patients
(conservative strategy). The authors prospectively
enrolled 11,372 consecutive stable angina patients
who were referred for SPECT or cardiac catheteriza-
tion. It was shown that stable chest pain patients who
underwent a more aggressive diagnostic strategy had
higher diagnostic costs and greater rates of interven-
tion and follow-up costs. In the EMPIRE study,
Underwood et al. [44] showed that investigative
strategies using myocardial perfusion imaging were
cheaper and equally effective when compared with
strategies that did not use myocardial perfusion
imaging, both for cost of diagnosis and for over-
all 2 year management costs. In an ongoing study,
Groothuis et al. [45] combines multi-detector CT and
CMR to provide the clinician a strategy with the aim
to comprehensively evaluate coronary morphology
and function noninvasively. In the MARCC trial
(Magnetic Resonance and CT in suspected CAD)
a new noninvasive diagnostic work-up for patients
with suspected CAD will be developed, involving the
sequential use of both imaging techniques.
Although the results of the current study are still
preliminary, Pilz et al. [42] have clearly shown that
procedural costs in patients suspected for CAD would
substantially decrease when CMR is routinely applied
as a gatekeeper to cardiac catheterization.
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